AC Immune Ltd is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer's and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson's, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms. The Company's pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn, among others.
EPFL Innovation Park, Building B
The company trades on NASDAQ exchange. The company headquarter is located in Switzerland. The company was established in the 2003.| Ticker | ACIU |
| Long Name | AC Immune SA |
| Short Name | AC Immune SA |